268 related articles for article (PubMed ID: 21687663)
1. Inhibition of cell proliferation by an anti-EGFR aptamer.
Li N; Nguyen HH; Byrom M; Ellington AD
PLoS One; 2011; 6(6):e20299. PubMed ID: 21687663
[TBL] [Abstract][Full Text] [Related]
2. Pyrene-Modified DNA Aptamers with High Affinity to Wild-Type EGFR and EGFRvIII.
Zavyalova E; Turashev A; Novoseltseva A; Legatova V; Antipova O; Savchenko E; Balk S; Golovin A; Pavlova G; Kopylov A
Nucleic Acid Ther; 2020 Jun; 30(3):175-187. PubMed ID: 31990606
[TBL] [Abstract][Full Text] [Related]
3. Aptamer targeting EGFRvIII mutant hampers its constitutive autophosphorylation and affects migration, invasion and proliferation of glioblastoma cells.
Camorani S; Crescenzi E; Colecchia D; Carpentieri A; Amoresano A; Fedele M; Chiariello M; Cerchia L
Oncotarget; 2015 Nov; 6(35):37570-87. PubMed ID: 26461476
[TBL] [Abstract][Full Text] [Related]
4. DNA aptamers that target human glioblastoma multiforme cells overexpressing epidermal growth factor receptor variant III in vitro.
Tan Y; Shi YS; Wu XD; Liang HY; Gao YB; Li SJ; Zhang XM; Wang F; Gao TM
Acta Pharmacol Sin; 2013 Dec; 34(12):1491-8. PubMed ID: 24304919
[TBL] [Abstract][Full Text] [Related]
5. Study of the Function of G-Rich Aptamers Selected for Lung Adenocarcinoma.
Hu J; Zhao Z; Liu Q; Ye M; Hu B; Wang J; Tan W
Chem Asian J; 2015 Jul; 10(7):1519-25. PubMed ID: 25864879
[TBL] [Abstract][Full Text] [Related]
6. A neutralizing RNA aptamer against EGFR causes selective apoptotic cell death.
Esposito CL; Passaro D; Longobardo I; Condorelli G; Marotta P; Affuso A; de Franciscis V; Cerchia L
PLoS One; 2011; 6(9):e24071. PubMed ID: 21915281
[TBL] [Abstract][Full Text] [Related]
7. Efficient Epidermal Growth Factor Receptor Targeting Oligonucleotide as a Potential Molecule for Targeted Cancer Therapy.
Wang T; Philippovich S; Mao J; Veedu RN
Int J Mol Sci; 2019 Sep; 20(19):. PubMed ID: 31546749
[TBL] [Abstract][Full Text] [Related]
8. Aptamer-mediated delivery of chemotherapy to pancreatic cancer cells.
Ray P; Cheek MA; Sharaf ML; Li N; Ellington AD; Sullenger BA; Shaw BR; White RR
Nucleic Acid Ther; 2012 Oct; 22(5):295-305. PubMed ID: 23030589
[TBL] [Abstract][Full Text] [Related]
9. Selection of DNA aptamers against epidermal growth factor receptor with high affinity and specificity.
Wang DL; Song YL; Zhu Z; Li XL; Zou Y; Yang HT; Wang JJ; Yao PS; Pan RJ; Yang CJ; Kang DZ
Biochem Biophys Res Commun; 2014 Oct; 453(4):681-5. PubMed ID: 25242523
[TBL] [Abstract][Full Text] [Related]
10. RNA Aptamers for Theranostics of Glioblastoma of Human Brain.
Kopylov AM; Fab LV; Antipova O; Savchenko EA; Revishchin AV; Parshina VV; Pavlova SV; Kireev II; Golovin AV; Usachev DY; Pavlova GV
Biochemistry (Mosc); 2021 Aug; 86(8):1012-1024. PubMed ID: 34488577
[TBL] [Abstract][Full Text] [Related]
11. Aptamers as Reversible Sorting Ligands for Preparation of Cells in Their Native State.
Gray BP; Requena MD; Nichols MD; Sullenger BA
Cell Chem Biol; 2020 Feb; 27(2):232-244.e7. PubMed ID: 31879266
[TBL] [Abstract][Full Text] [Related]
12. PET imaging of EGFR expression using an
Cheng S; Jacobson O; Zhu G; Chen Z; Liang SH; Tian R; Yang Z; Niu G; Zhu X; Chen X
Eur J Nucl Med Mol Imaging; 2019 Apr; 46(4):948-956. PubMed ID: 30069577
[TBL] [Abstract][Full Text] [Related]
13. Anti-EGF Receptor Aptamer-Guided Co-Delivery of Anti-Cancer siRNAs and Quantum Dots for Theranostics of Triple-Negative Breast Cancer.
Kim MW; Jeong HY; Kang SJ; Jeong IH; Choi MJ; You YM; Im CS; Song IH; Lee TS; Lee JS; Lee A; Park YS
Theranostics; 2019; 9(3):837-852. PubMed ID: 30809312
[TBL] [Abstract][Full Text] [Related]
14. Aptamers selected against the unglycosylated EGFRvIII ectodomain and delivered intracellularly reduce membrane-bound EGFRvIII and induce apoptosis.
Liu Y; Kuan CT; Mi J; Zhang X; Clary BM; Bigner DD; Sullenger BA
Biol Chem; 2009 Feb; 390(2):137-44. PubMed ID: 19040357
[TBL] [Abstract][Full Text] [Related]
15. Monitoring of the Binding Between EGFR Protein and EGFR Aptamer Using In-Situ Total Internal Reflection Ellipsometry.
Kang YR; Byun JS; Kim TJ; Park HG; Park JC; Barange N; Nam KH; Kim YD
J Nanosci Nanotechnol; 2016 Jun; 16(6):6445-9. PubMed ID: 27427733
[TBL] [Abstract][Full Text] [Related]
16. Anti-FGFR1 aptamer-tagged superparamagnetic conjugates for anticancer hyperthermia therapy.
Jurek PM; Zabłocki K; Waśko U; Mazurek MP; Otlewski J; Jeleń F
Int J Nanomedicine; 2017; 12():2941-2950. PubMed ID: 28442904
[TBL] [Abstract][Full Text] [Related]
17. Aptamer to ErbB-2/HER2 enhances degradation of the target and inhibits tumorigenic growth.
Mahlknecht G; Maron R; Mancini M; Schechter B; Sela M; Yarden Y
Proc Natl Acad Sci U S A; 2013 May; 110(20):8170-5. PubMed ID: 23630281
[TBL] [Abstract][Full Text] [Related]
18. Directed evolution of gold nanoparticle delivery to cells.
Li N; Larson T; Nguyen HH; Sokolov KV; Ellington AD
Chem Commun (Camb); 2010 Jan; 46(3):392-4. PubMed ID: 20066302
[TBL] [Abstract][Full Text] [Related]
19. Epidermal growth factor receptor coexpression modulates susceptibility to Herceptin in HER2/neu overexpressing breast cancer cells via specific erbB-receptor interaction and activation.
Diermeier S; Horváth G; Knuechel-Clarke R; Hofstaedter F; Szöllosi J; Brockhoff G
Exp Cell Res; 2005 Apr; 304(2):604-19. PubMed ID: 15748904
[TBL] [Abstract][Full Text] [Related]
20. d-/l-Isothymidine incorporation in the core sequence of aptamer BC15 enhanced its binding affinity to the hnRNP A1 protein.
Li L; Yang X; Li K; Zhang G; Ma Y; Cai B; Li S; Ding H; Deng J; Nan X; Sun J; Wu Y; Shao N; Zhang L; Yang Z
Org Biomol Chem; 2018 Oct; 16(40):7488-7497. PubMed ID: 30272759
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
